SHARE Study 4: Financial Incentives for Weight Loss
Phase 3
Completed
- Conditions
- Obesity
- Registration Number
- NCT02008474
- Lead Sponsor
- The Miriam Hospital
- Brief Summary
The purpose of this study is to examine different types of monetary incentive paradigms for weight loss.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- BMI >=25kg/m2
- English speaking
- Age 18-70
Exclusion Criteria
- Health problems that make weight loss or unsupervised exercise unsafe
- Current pregnancy or plan to become pregnant int he next 12 months
- Planned relocation
- Current participation in weight loss research study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method weight change from initial assessment to the 3-month follow-up assessment measured on a digital scale to the nearest 0.1-kilogram 0 to 3 months
- Secondary Outcome Measures
Name Time Method weight change from the initial assessment to the 12 month assessment measured on a digital scale to the nearest 0.1-kilogram 0 to 12 months Weight change from the 3 month assessment to the 12 month assessment measured on a digital scale to the nearest 0.1-kilogram 3 to 12 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the effectiveness of financial incentives in behavioral weight loss interventions for obesity?
How do the behavioral weight loss strategies in NCT02008474 compare to standard-of-care pharmacotherapies like GLP-1 receptor agonists in terms of efficacy and adherence?
Are there specific biomarkers, such as adipokine profiles or genetic variants, that predict response to incentive-based behavioral weight loss programs in obese populations?
What adverse events are associated with incentive-based behavioral interventions for obesity, and how do they compare to those of bariatric surgery or SGLT2 inhibitors?
How do combination approaches of financial incentives with pharmacological agents like semaglutide or liraglutide enhance long-term weight loss outcomes in clinical trials?
Trial Locations
- Locations (1)
The Miriam Hospital's Weight Control and Diabetes Research Center
🇺🇸Providence, Rhode Island, United States
The Miriam Hospital's Weight Control and Diabetes Research Center🇺🇸Providence, Rhode Island, United States